
Prognostic Stratification Using Dobutamine Stress ^{99m}Tc -Tetrofosmin Myocardial Perfusion SPECT in Elderly Patients Unable to Perform Exercise Testing

Arend F.L. Schinkel, MD, PhD¹; Abdou Elhendy, MD, PhD¹; Elena Biagini, MD¹; Ron T. van Domburg, PhD¹; Roelf Valkema, MD, PhD²; Vittoria Rizello, MD¹; Chiara Pedone, MD¹; Maarten Simoons, MD, PhD¹; Jeroen J. Bax, MD, PhD³; and Don Poldermans, MD, PhD¹

¹Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands; ²Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands; and ³Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands

Information on the prognostic value of noninvasive stress imaging techniques in the elderly is relatively scarce. This study assessed the prognostic value of dobutamine stress ^{99m}Tc -tetrofosmin SPECT for the prediction of mortality and cardiac events in elderly patients. **Methods:** Clinical information and SPECT results were analyzed for 272 consecutive patients \geq 65 y old (mean age, 71 ± 5 y; range, 65–87 y) with limited exercise capacity. Follow-up was complete in 270 patients (99.3%); 23 underwent revascularization within 60 d of the scintigraphy and were excluded. Abnormal findings were defined as the presence of a fixed or reversible perfusion defect. A summed stress score was obtained to estimate the extent and severity of perfusion defects. The incremental prognostic value of SPECT over clinical data was evaluated according to 3 multivariate models, which included any SPECT abnormality, the presence of a fixed or reversible defect, and the summed stress score. **Results:** During the follow-up (3.3 ± 1.4 y), 59 patients died (29 cardiac deaths), 16 had a nonfatal infarction, and 49 underwent late revascularization. Abnormal scan findings were present for 140 patients (57%). The annual event rates for total mortality, cardiac death, and cardiac death or nonfatal infarction were, respectively, 3.2%, 0.2%, and 0.7% when scan findings were normal and, respectively, 9.5%, 4.3%, and 8% when scan findings were abnormal (all $P < 0.0001$). Multivariate analysis showed that abnormal scan findings, the presence of a fixed or reversible defect, and the summed stress score provided incremental prognostic information over clinical data. The presence of abnormal scan findings was independently associated with an increased risk for total mortality, cardiac death, and cardiac death or nonfatal infarction (respectively, hazard ratio 3.4 [95% CI, 1.8–6.5], 12.1 [95% CI, 2.9–51.5], and 9.0 [95% CI, 2.8–29.6]). **Conclusion:** Dobutamine stress ^{99m}Tc -tetrofosmin

SPECT provides incremental prognostic information for the prediction of total mortality and cardiac events in elderly patients.

Key Words: ^{99m}Tc -tetrofosmin; scintigraphy; dobutamine; prognosis; elderly

J Nucl Med 2005; 46:12–18

The population of the Western world is aging, and the proportion of elderly patients in cardiovascular practice will further increase in the next 2 decades (1). Cardiovascular disease is the most common cause of morbidity and mortality in patients older than 65 y (1). Coronary angioplasty and coronary bypass surgery have become more available for elderly patients and may substantially improve short- and long-term outcome in high-risk patients (2). Prognostic evaluation in elderly patients with suspected or known coronary artery disease can distinguish high-risk patients who may benefit from an invasive approach from low-risk patients who do not require invasive procedures. Unfortunately, information on prognostic stratification by noninvasive testing in elderly patients is relatively limited (3,4). The feasibility of exercise stress testing in elderly patients is often unsatisfactory because of lack of physical fitness and the presence of comorbid conditions such as degenerative joint disease, claudication, and peripheral neuropathy. Pharmacologic stress myocardial perfusion SPECT is a feasible alternative. However, data on the prognostic value of this technique in elderly patients are scarce (3,4). The purpose of this study was to determine the prognostic value of dobutamine ^{99m}Tc -tetrofosmin SPECT for the prediction of total mortality and cardiac events in elderly patients unable to perform exercise testing.

Received May 24, 2004; revision accepted Aug. 12, 2004.
For correspondence or reprints contact: Arend F.L. Schinkel, MD, PhD, Thoraxcenter Room Ba 302, Erasmus Medical Center, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
E-mail: arendschinkel@hetnet.nl

MATERIALS AND METHODS

Study Population

A total of 272 consecutive patients ≥ 65 y old and unable to perform exercise testing underwent dobutamine stress ^{99m}Tc -tetrofosmin SPECT for the evaluation of suspected or known coronary artery disease. Follow-up was complete for 270 (99.3%) of 272 patients. Twenty-three patients underwent myocardial revascularization within 60 d of the scintigraphy and were excluded from analysis. This exclusion was based on previous data indicating that in the first 60 d after the test, referral for myocardial revascularization tends to be based on the SPECT results, whereas >60 d after testing, referral for myocardial revascularization tends to be based on deterioration of the patient's clinical status (5). Accordingly, the prognostic data reported are based on 247 patients. A total of 48 patients (19%) were >75 y old. In 119 patients (48%), the stress myocardial perfusion imaging was performed to evaluate known coronary artery disease; 89 of them had a previous myocardial infarction, and 30 had proven coronary artery disease without previous infarction. The remaining 128 patients (52%) had suspected coronary artery disease and underwent imaging for diagnostic reasons. Ninety-seven patients (39%) had typical angina, 60 (24%) had atypical angina, and 34 (14%) had nonanginal symptoms. All patients gave informed consent before the test. The local Medical Ethics Committee approved the study protocol.

Before dobutamine stress ^{99m}Tc -tetrofosmin SPECT, a structured clinical interview and history were acquired and cardiac risk factors were assessed. Hypertension was defined as a blood pressure $\geq 140/90$ mm Hg or treatment with antihypertensive medication. Diabetes mellitus was defined as a fasting glucose level ≥ 7.8 mmol/L or the need for insulin or oral hypoglycemic medication. Hypercholesterolemia was defined as a total cholesterol ≥ 6.4 mmol/L or treatment with lipid-lowering medication.

Dobutamine Stress Testing

Dobutamine stress testing was performed according to a standard protocol as previously reported (6). Dobutamine was infused through the antecubital vein, starting at a dose of 10 $\mu\text{g}/\text{kg}/\text{min}$ for 3 min and increasing by 10 $\mu\text{g}/\text{kg}/\text{min}$ every 3 min up to a maximum dose of 40 $\mu\text{g}/\text{kg}/\text{min}$. If the test endpoint was not reached at a dobutamine dose of 40 $\mu\text{g}/\text{kg}/\text{min}$, atropine (up to 1 mg) was given intravenously. Blood pressure and heart rate were monitored and electrocardiography was recorded constantly. Test endpoints were achievement of target heart rate (85% of maximum age- and sex-predicted heart rate); horizontal or downsloping ST-segment depression > 2 mm at an interval of 80 ms after the J-point, compared with baseline; ST-segment elevation > 1 mm in patients without previous myocardial infarction; severe angina; a systolic blood pressure fall > 40 mm Hg, compared with baseline; blood pressure $> 240/120$ mm Hg; or significant cardiac arrhythmias. Metoprolol was available to reverse the adverse effects of dobutamine/atropine.

SPECT

Approximately 1 min before the termination of the stress test, an intravenous dose of 370 MBq of ^{99m}Tc -tetrofosmin was administered (6). For resting studies, 370 MBq of tetrofosmin were injected at least 24 h after the stress study. Image acquisition was performed with a triple-head γ -camera system (Prism 3000 XP; Picker International). For each study, 6 oblique (short axis) slices from the apex to the base and 3 sagittal (vertical long axis) slices

were defined. Each of the 6 short-axis slices was divided into 8 equal segments. The septal part of the 2 basal slices was excluded from analysis because this region corresponds to the fibrous portion of the interventricular septum and normally exhibits reduced uptake. Therefore, 47 segments were identified (3 long axis and 44 short axis). The SPECT scoring model has been described previously (6) and has been depicted previously by Salustri et al. (7). The scan was interpreted semiquantitatively by visual analysis assisted by analysis of the circumferential profiles. Rest and stress images were evaluated by measuring the area between the lower limit of normal and the actual circumferential profile in 6 short-axis slices. Profile curves 2 SDs below normal perfusion were considered abnormal. Stress and rest tomographic views were reviewed side by side by an experienced observer who was unaware of each patient's clinical data. A reversible perfusion defect was defined as a perfusion defect on stress images that partially or completely resolved at rest in ≥ 2 contiguous segments or slices in the 47-segment model. A fixed perfusion defect was defined as a perfusion defect on stress images in ≥ 2 contiguous segments or slices that persisted on rest images in the 47-segment model. A study was considered to have abnormal findings if a fixed or reversible perfusion defect (or both) was present. To identify the coronary artery related to the location of the perfusion defect, the 47 segments imaged by SPECT were combined into 6 major regions: anterior, inferior, septal anterior, septal posterior, posterolateral, and apical. This combination provides easily interpretable information for the treating cardiologist. Each of the 6 major left ventricular segments was scored using a 4-grade scoring method (0 = normal, 1 = slightly reduced, 2 = moderately reduced, and 3 = severely reduced or absence of uptake). The perfusion defect score was derived by summing the score of the 6 myocardial segments at stress (summed stress score).

Patient Follow-up

The follow-up data were obtained by reviewing hospital records and by contacting the patient's general practitioner. The date of the last examination or consultation was used to determine follow-up time. Endpoints were overall death, cardiac death, nonfatal myocardial infarction, and late (>60 d) coronary revascularization. Cardiac death was defined as death caused by myocardial infarction, significant cardiac arrhythmias, or refractory congestive heart failure. Sudden death occurring without another explanation was included as cardiac death. Myocardial infarction was defined according to standard criteria (8).

Statistical Analysis

Continuous data were expressed as mean \pm SD, and percentages were rounded. Statistical analysis was performed with the BMDP statistical software package (BMDP Statistical Software Inc.). Continuous variables were compared using the Student *t* test for unpaired samples. Differences between proportions were compared using the χ^2 test. Univariate and multivariate Cox proportional hazards regression models were used to identify independent predictors of total mortality and cardiac events (9). Variables were selected in a stepwise forward-selection manner, with entry and retention set at a significance level of 0.05. The risk of a variable was expressed as a hazard ratio with a corresponding 95% confidence interval. The incremental value of myocardial perfusion scintigraphy over the clinical variables in the prediction of events was determined according to 3 models. In model 1, the incremental value of abnormal scan findings over clinical data and stress test

information was assessed. In model 2, the presence of a fixed or reversible defect was entered. In model 3 the summed stress score was entered. The probability of survival was calculated using the Kaplan–Meier method, and survival curves were compared using the log-rank test. $P < 0.05$ was considered statistically significant.

RESULTS

Demographics and Stress Test Results

Clinical data are presented in Table 1. Dobutamine stress increased heart rate significantly (from 72 ± 15 to 128 ± 16 bpm, $P < 0.001$) and increased systolic blood pressure modestly (from 140 ± 23 to 146 ± 31 mm Hg, $P < 0.001$). The highest dobutamine dose was $10 \mu\text{g}/\text{kg}/\text{min}$ in 1 patient (0.4%), $20 \mu\text{g}/\text{kg}/\text{min}$ in 44 (18%), $30 \mu\text{g}/\text{kg}/\text{min}$ in 45 (18%), and $40 \mu\text{g}/\text{kg}/\text{min}$ in 157 (64%). In 88 patients (36%), atropine was added. Patients who were using β -blocker therapy during the dobutamine stress test more frequently received atropine than did patients not receiving β -blocker therapy (54 of 105, 51%, vs. 34 of 142, 24%, $P < 0.001$). Side effects that occurred during dobutamine stress testing were generally self-limiting. These included atrial fibrillation in 5 patients (2.0%), short ventricular tachycardia (<10 complexes) in 6 patients (2.4%), and severe hypotension (decrease in systolic blood pressure > 40 mm Hg) in 4 patients (1.6%). Minor side effects included nausea in 4 (1.6%), flushing in 3 (1.2%), and headache in 13 (5.3%). No patient experienced a myocardial infarction or ventricular fibrillation during or immediately after the stress test.

SPECT and Outcome Events

A total of 107 patients (43%) had normal perfusion, and 140 (57%) had abnormal perfusion. In these 140 patients,

TABLE 1
Clinical Characteristics

Characteristic	No. of patients	Percentage
Total patients*	247	100
Male patients	129	52
Systemic hypertension	102	41
Diabetes mellitus	47	19
Smoking	52	21
Hypercholesterolemia	74	30
Congestive heart failure	40	16
β -blockers	105	43
Calcium channel blockers	111	45
Angiotensin-converting enzyme inhibitors	69	28
Diuretics	66	27
History of myocardial infarction	89	36
History of coronary angioplasty	44	18
History of coronary artery bypass surgery	48	19

*Age range, 65–87 y; mean \pm SD, 71 ± 5 y.




FIGURE 1. Kaplan–Meier survival curves for total mortality according to results of dobutamine stress $^{99\text{m}}\text{Tc}$ -tetrofosmin SPECT.

perfusion abnormalities were reversible in 20 (14%), fixed in 67 (48%), and both fixed and reversible (or partially reversible) in 53 (38%). During a mean follow-up of 3.3 ± 1.4 y, 59 deaths (24%) occurred, of which 29 (12%) were due to cardiac causes. Nonfatal myocardial infarction occurred in 16 patients (6%). Forty-nine patients (20%) underwent late (>60 d) myocardial revascularization (28 patients had coronary bypass surgery, and 21 had coronary angioplasty).

Predictive Value of Clinical Data and Test Results

Kaplan–Meier survival curves and cumulative event rates are presented in Figures 1–3. Patients with normal perfusion had a low event rate. Remarkably, no cardiac deaths occurred during the first 3 y after the test in those whose test results were normal. Survival curves continued to diverge during follow-up, indicating that the prognostic value of dobutamine stress $^{99\text{m}}\text{Tc}$ -tetrofosmin SPECT was maintained over time. The annual event rates for total mortality, cardiac death, and cardiac death or nonfatal infarction were, respectively, 3.2%, 0.2%, and 0.7% after a scan with normal findings and, respectively, 9.5%, 4.3%, and 8% after a scan with abnormal findings (all $P < 0.0001$).

Univariate and multivariate predictors of total mortality and cardiac events are presented in Tables 2–4. The




FIGURE 2. Kaplan–Meier survival curves for cardiac death according to results of dobutamine stress $^{99\text{m}}\text{Tc}$ -tetrofosmin SPECT.




FIGURE 3. Kaplan–Meier survival curves for cardiac death or nonfatal myocardial infarction according to results of dobutamine stress ^{99m}Tc -tetrofosmin SPECT.

incremental prognostic value of dobutamine stress ^{99m}Tc -tetrofosmin SPECT over clinical data was assessed using the 3 models. All models provided incremental information over clinical and stress test data. Model 1, which included any abnormal scan finding, offered the most powerful incremental information for the prediction of total mortality (global $\chi^2 = 26$; $P < 0.05$). Model 2, which included both fixed and reversible perfusion defects, provided the most powerful incremental information for the prediction of cardiac death, as well as of cardiac death or nonfatal infarction (global $\chi^2 = 53$ and 51, respectively; $P < 0.0001$).

DISCUSSION

This study assessed the prognostic value of dobutamine stress ^{99m}Tc -tetrofosmin SPECT in the prediction of mortality and hard cardiac events in elderly patients. Despite their advanced age, patients with normal myocardial perfusion findings had an excellent outcome, with no cardiac deaths during the first 3 y after a normal test. In contrast, patients with abnormal myocardial perfusion findings had an elevated risk of future cardiac events. ^{99m}Tc -Tetrofosmin SPECT provided prognostic information incremental to clinical and stress test parameters for the prediction of total mortality and cardiac events during a nearly complete follow-up of 3.3 ± 1.4 y. Independent clinical predictors of total mortality were smoking and congestive heart failure. Independent clinical predictors of cardiac events were diabetes mellitus, smoking, and congestive heart failure. Furthermore, the presence of a left bundle branch block was predictive of cardiac death. ^{99m}Tc -Tetrofosmin SPECT provided incremental prognostic information over clinical and stress test parameters. The multivariate model that included any scan abnormality provided the most powerful incremental information for the prediction of total mortality. The multivariate model that included both fixed and reversible perfusion defects offered the most powerful incremental information for the prediction of cardiac death, as

TABLE 2
Univariate and Multivariate Predictors of Total Mortality

Parameter	Univariate	Multivariate			
		Clinical data	Model 1	Model 2	Model 3
Clinical characteristics					
Male patient	1.6 (0.9–2.9)	NS	NS	NS	NS
Previous infarction	1.4 (0.8–2.6)	NS	NS	NS	NS
Diabetes mellitus	1.7 (0.8–3.3)	NS	NS	NS	NS
Hypertension	1.3 (0.7–2.3)	NS	NS	NS	NS
Hypercholesterolemia	0.7 (0.4–1.4)	NS	NS	NS	NS
Smoking	3.1 (1.4–7.1)	1.9 (1.1–3.3)	NS	NS	NS
Heart failure	2.9 (1.4–6.0)	2.4 (1.3–4.2)	2.5 (1.4–4.3)	2.5 (1.4–4.4)	2.3 (1.3–4.1)
Left bundle branch block	2.0 (0.7–5.8)	NS	NS	NS	NS
Stress test results					
Angina pectoris	1.0 (0.5–1.9)	—	NS	NS	NS
ST-segment changes	1.4 (0.8–2.7)	—	NS	NS	NS
Peak heart rate	0.9 (0.4–2.1)	—	NS	NS	NS
Scan parameters					
Abnormal findings	3.7 (1.9–7.5)	—	3.4 (1.8–6.5)	—	—
Fixed defect	2.6 (1.4–4.7)	—	—	NS	—
Reversible defect	2.1 (1.2–4.0)	—	—	2.2 (1.3–3.8)	—
Summed stress score/10	5.2 (2.0–12)	—	—	—	4.4 (1.8–11)
Global χ^2		16	26	20	20
Incremental value over clinical data			$P < 0.05$	$P < 0.05$	$P < 0.05$

NS = not significant; — = variable excluded.


Data are Cox proportional hazard ratio, with 95% confidence interval in parentheses. In model 1, the variable entered was the presence of an abnormal scan; in model 2, the presence of a fixed or reversible defect was entered; in model 3, the summed stress score was entered.

TABLE 3
Univariate and Multivariate Predictors of Cardiac Death

Parameter	Univariate	Multivariate			
		Clinical data	Model 1	Model 2	Model 3
Clinical characteristics					
Male patient	1.0 (0.5–2.1)	NS	NS	NS	NS
Previous infarction	1.1 (0.5–2.4)	NS	NS	NS	NS
Diabetes mellitus	3.1 (1.3–7.1)	2.9 (1.4–6.1)	2.8 (1.3–6.3)	2.6 (1.2–6.0)	2.7 (1.2–5.9)
Hypertension	1.6 (0.7–3.5)	NS	NS	NS	NS
Hypercholesterolemia	0.9 (0.4–2.1)	NS	NS	NS	NS
Smoking	3.1 (1.4–7.1)	2.4 (1.1–5.0)	2.3 (1.1–5.2)	2.8 (1.3–6.1)	NS
Heart failure	4.0 (1.7–9.4)	3.4 (1.6–7.4)	3.5 (1.6–7.7)	2.8 (1.3–6.4)	3.1 (1.4–6.8)
Left bundle branch block	5.3 (1.7–16)	NS	3.2 (1.3–8.3)	3.0 (1.2–7.7)	NS
Stress test results					
Angina pectoris	0.8 (0.3–2.1)	—	NS	NS	NS
ST-segment changes	1.2 (0.5–2.7)	—	NS	NS	NS
Peak heart rate	1.1 (0.2–5.0)	—	NS	NS	NS
Scan parameters					
Abnormal findings	11.8 (2.7–51)	—	12.1 (2.9–52)	—	—
Fixed defect	3.2 (1.3–7.4)	—	—	3.1 (1.5–6.8)	—
Reversible defect	3.5 (1.6–7.7)	—	—	4.5 (2.1–9.6)	—
Summed stress score/10	6.7 (2.1–22)	—	—	—	6.7 (2.0–23)
Global χ^2		25	47	53	28
Incremental value over clinical data			$P < 0.0001$	$P < 0.0001$	$P < 0.05$

NS = not significant; — = variable excluded.

Data are Cox proportional hazard ratio, with 95% confidence interval in parentheses. In model 1, the variable entered was the presence of an abnormal scan; in model 2, the presence of a fixed or reversible defect was entered; in model 3, the summed stress score was entered.



well as of cardiac death or nonfatal infarction. Moreover, multivariate analysis showed that the summed stress score, which indicates the extent and severity of perfusion abnormalities, provided incremental prognostic information over clinical data. These results demonstrate that the evaluation of elderly patients using dobutamine stress ^{99m}Tc -tetrofosmin SPECT is a safe and feasible method that provides clinically useful information on clinical outcome.

Previous data indicate that dobutamine stress ^{99m}Tc -tetrofosmin SPECT is safe and feasible in elderly patients (10). However, information on the prognostic value of stress myocardial perfusion imaging in the elderly is scarce. Furthermore, there are no data to support a role of stress myocardial perfusion imaging in the prediction of all causes of mortality in the elderly. Currently, prognostic data on sestamibi SPECT in the elderly are not available. Iskandrian et al. (11) assessed the use of exercise ^{201}Tl imaging for the prognostic stratification of 404 elderly patients with a mean age of 65 y (range, 60–82 y). During a follow-up of 25 ± 15 mo, 8 (2%) died of cardiac causes, and 10 (2%) had nonfatal myocardial infarction. Patients with abnormal exercise ^{201}Tl findings had higher event rates than did those with normal findings (8% vs. 1%, $P < 0.001$). Steingart et al. (12) followed 578 patients aged 65 y or older (range, 65–85 y) using exercise myocardial perfusion imaging.

Almost 80% underwent ^{201}Tl SPECT; the remainder underwent ^{99m}Tc -sestamibi imaging. During a follow-up of 4.4 ± 1.3 y, 39 deaths and 17 nonfatal myocardial infarctions occurred. The authors concluded that treadmill exercise is a valuable tool in elderly patients with adequate exercise capacity and that myocardial perfusion imaging added only modest prognostic information. The event rate was lower than for our study, as may be explained by our inclusion of patients unable to perform exercise testing, who are generally recognized as a higher-risk group, compared with patients who can exercise (13). Shaw et al. (14) studied 348 patients ≥ 70 y old using dipyridamole ^{201}Tl imaging. During a follow-up of 23 ± 15 mo, there were 52 cardiac deaths (15%) and 24 nonfatal myocardial infarctions (7%). The event rate for cardiac death or nonfatal infarction was 2% in patients with normal scan findings and 20% in patients with abnormal scan findings. Abnormal (reversible or fixed perfusion defect) dipyridamole ^{201}Tl findings were the best predictor of cardiac events.

The 0.7% hard cardiac event rate in patients with normal dobutamine stress ^{99m}Tc -tetrofosmin SPECT findings is substantially lower than the hard cardiac event rate in patients with normal ^{201}Tl findings (11,12,14). This difference may be related to the better imaging characteristics of ^{99m}Tc -tetrofosmin than of ^{201}Tl . Clinical trials have demon-

TABLE 4
Univariate and Multivariate Predictors of Cardiac Death or Myocardial Infarction

Parameter	Univariate	Multivariate			
		Clinical data	Model 1	Model 2	Model 3
Clinical characteristics					
Male patient	1.8 (0.9–3.6)	NS	NS	NS	NS
Previous infarction	1.5 (0.7–2.9)	NS	NS	NS	NS
Diabetes mellitus	2.6 (1.2–5.5)	2.6 (1.3–5.1)	2.6 (1.3–5.2)	2.3 (1.1–4.8)	2.2 (1.1–4.5)
Hypertension	1.3 (0.6–2.5)	NS	NS	NS	NS
Hypercholesterolemia	0.9 (0.4–1.9)	NS	NS	NS	NS
Smoking	3.3 (1.6–6.9)	2.5 (1.3–4.8)	2.1 (1.1–4.1)	2.7 (1.4–5.2)	NS
Heart failure	3.0 (1.3–6.7)	3.0 (1.5–6.0)	3.2 (1.6–6.4)	2.6 (1.3–5.5)	2.6 (1.3–5.4)
Left bundle branch block	3.7 (1.2–11)	NS	NS	NS	NS
Stress test results					
Angina pectoris	1.2 (0.6–2.6)	—	NS	NS	NS
ST-segment changes	1.0 (0.5–2.1)	—	NS	NS	NS
Peak heart rate	0.8 (0.2–3.6)	—	NS	NS	NS
Scan parameters					
Abnormal findings	7.8 (2.7–23)	—	9.0 (2.8–30)	—	—
Fixed defect	3.2 (1.5–6.8)	—	—	2.9 (1.5–5.8)	—
Reversible defect	2.7 (1.3–5.5)	—	—	3.9 (2.0–7.7)	—
Summed stress score/10	15.1 (5.3–47)	—	—	—	13.1 (4.1–42)
Total χ^2		27	45	51	36
Incremental value over clinical data			$P < 0.0001$	$P < 0.0001$	$P < 0.001$

NS = not significant; — = variable excluded.

Data are Cox proportional hazard ratio, with 95% confidence interval in parentheses. In model 1, the variable entered was the presence of an abnormal scan; in model 2, the presence of a fixed or reversible defect was entered; in model 3, the summed stress score was entered.

strated that ^{99m}Tc -tetrofosmin SPECT provides diagnostic and prognostic information comparable to that derived from traditional ^{201}Tl imaging, with the extra benefit of higher image quality and increased certainty in interpretation (15–17). This study expands the body of literature regarding the prognostic utility of this relatively new radioactive isotope in patients with known or suspected coronary artery disease. The study also is, to our knowledge, the first to support a role of stress myocardial perfusion imaging in the prediction of all causes of mortality in the elderly. The present data indicate that elderly patients with normal dobutamine stress ^{99m}Tc -tetrofosmin myocardial perfusion findings have a favorable prognosis during the 3 y after the study if no change in clinical status occurs. There have been several attempts to quantify the low-risk period after a scan with normal findings is obtained (18). Prognostic information derived from exercise sestamibi SPECT demonstrates that repeated testing should be not required up to 4 or 5 y after a study with normal findings; however, when symptoms arise or clinical status changes, retesting and subsequent angiography and revascularization may be required (19). Further studies are needed to confirm these data in elderly patients. The left ventricular ejection fraction was not available in all patients; this is a limitation of the study.

CONCLUSION

Dobutamine stress ^{99m}Tc -tetrofosmin SPECT provides incremental prognostic information for the prediction of all causes of mortality and hard cardiac events in the elderly. Elderly patients with normal myocardial perfusion findings have a good prognosis and do not require further invasive evaluation during the 3 y after the study if no change in clinical status occurs.

REFERENCES

1. Foot DK, Lewis RP, Pearson TA, et al. Demographics and cardiology, 1950–2050. *J Am Coll Cardiol*. 2000;35:66B–88B.
2. The TIME investigators. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary artery disease (TIME): a randomized trial. *Lancet*. 2001;358:951–957.
3. Beller GA, Zaret BL. Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease. *Circulation*. 2000;101:1465–1478.
4. Elhendy A, Bax JJ, Poldermans D. Dobutamine stress myocardial perfusion imaging in coronary artery disease. *J Nucl Med*. 2002;43:1634–1646.
5. Hachamovitch R, Berman DS, Kiat H, et al. Exercise myocardial perfusion SPECT in patients without known coronary artery disease: incremental prognostic value and use in risk stratification. *Circulation*. 1996;93:905–914.
6. Schinkel AFL, Elhendy A, van Domburg RT, Bax JJ, Roelandt JRTC, Poldermans D. Prognostic value of dobutamine-atropine stress (^{99m}Tc -tetrofosmin myocardial perfusion SPECT in patients with known or suspected coronary artery disease. *J Nucl Med*. 2002;43:767–772.

7. Salustri A, Pozzoli MMA, Hermans W, et al. Relationship between exercise echocardiography and perfusion single-photon emission computed tomography in patients with single-vessel coronary artery disease. *Am Heart J*. 1992;124:75–83.
8. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *Eur Heart J*. 2000;21:1502–1513.
9. Cox DR. Regression models and life-tables. *J R Stat Soc (B)*. 1972;34:187–202.
10. Elhendy A, van Domburg RT, Bax JJ, et al. Safety, hemodynamic profile, and feasibility of dobutamine stress technetium myocardial perfusion single-photon emission CT imaging for evaluation of coronary artery disease in the elderly. *Chest*. 2000;117:649–656.
11. Iskandrian AS, Heo J, Decoskey D, Askenase A, Segal BL. Use of exercise thallium-201 imaging for risk stratification of elderly patients with coronary artery disease. *Am J Cardiol*. 1988;61:269–272.
12. Steingart RM, Hodnett P, Musso J, Feuerman M. Exercise myocardial perfusion imaging in elderly patients. *J Nucl Cardiol*. 2002;9:573–580.
13. Calnon DA, McGrath PD, Doss AL, Harrell FE, Watson DD, Beller GA. Prognostic value of dobutamine stress technetium-99m-sestamibi single-photon emission computed tomography myocardial perfusion imaging: stratification of a high-risk population. *J Am Coll Cardiol*. 2001;38:1511–1517.
14. Shaw L, Chaitman BR, Hilton TC, et al. Prognostic value of dipyridamole thallium-201 imaging in elderly patients. *J Am Coll Cardiol*. 1992;19:1390–1398.
15. Rigo P, Leclercq B, Itti R, Lahiri A, Braat S. Technetium-99m-tetrofosmin myocardial imaging: a comparison with thallium-201 and angiography. *J Nucl Med*. 1994;35:587–593.
16. Tamaki N, Takahashi N, Kawamoto M, et al. Myocardial tomography using technetium-99m-tetrofosmin to evaluate coronary artery disease. *J Nucl Med*. 1994;35:594–600.
17. Zaret BL, Rigo P, Wackers FJ, et al. The tetrofosmin international trial study group: myocardial perfusion imaging with ^{99m}Tc-tetrofosmin—comparison to ²⁰¹Tl imaging and coronary angiography in a phase III multicenter trial. *Circulation*. 1995;91:313–319.
18. Thomas GS, Miyamoto MI. Is a revision of the “nuclear cardiology warranty” in order? *J Nucl Cardiol*. 2003;10:329–332.
19. Elhendy A, Schinkel AFL, Bax JJ, van Domburg RT, Poldermans D. Long-term prognosis after a normal exercise stress Tc-99m sestamibi SPECT study. *J Nucl Cardiol*. 2003;10:261–266.

